---
title: "China Shineway Pharma Sets 2026 AGM to Approve Results and Share Issuance Mandate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283813303.md"
description: "China Shineway Pharmaceutical Group Limited has scheduled its annual general meeting for May 28, 2026, in Hong Kong. Shareholders will review the audited financial statements for the year ended December 31, 2025, and vote on the re-election of three directors, directors’ remuneration, and the re-appointment of Deloitte as auditor. The agenda includes authorizing the board to issue new shares up to 20% of the company’s issued share capital, enhancing financial flexibility and potential funding capacity. This move aims to maintain governance continuity and readiness for growth in the competitive pharmaceutical sector."
datetime: "2026-04-23T10:12:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283813303.md)
  - [en](https://longbridge.com/en/news/283813303.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283813303.md)
---

# China Shineway Pharma Sets 2026 AGM to Approve Results and Share Issuance Mandate

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

China Shineway Pharmaceutical Group Limited ( (HK:2877) ) has provided an announcement.

China Shineway Pharmaceutical Group Limited has called its annual general meeting for 28 May 2026 in Hong Kong, where shareholders will review and adopt the audited financial statements, the directors’ report and the independent auditor’s report for the year ended 31 December 2025. The agenda also includes re-election of three directors, approval of directors’ remuneration, re-appointment of Deloitte Touche Tohmatsu as auditor, and authorization for the board to issue new shares and related instruments up to 20% of the company’s issued share capital, a move that preserves financial flexibility and potential funding capacity without immediately diluting existing shareholders.

By renewing its board composition and auditor mandate while seeking a general share-issuance authority, the company is maintaining continuity in governance and oversight as it enters the new financial year. The proposed share mandate, common among Hong Kong–listed issuers, positions China Shineway to respond quickly to capital needs or strategic opportunities, which may influence future capital structure and signal continued readiness to invest in growth within the competitive pharmaceutical sector.

**More about China Shineway Pharmaceutical Group Limited**

China Shineway Pharmaceutical Group Limited is a Hong Kong–listed pharmaceutical company engaged in the development, production and sale of medicinal products. The group focuses on traditional Chinese medicine and related pharmaceutical formulations, serving healthcare markets in Mainland China and broader Asian regions through its portfolio of branded therapies.

**Average Trading Volume:** 1,126,898

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$7.71B

### Related Stocks

- [02877.HK](https://longbridge.com/en/quote/02877.HK.md)

## Related News & Research

- [CANbridge Pharmaceuticals holds annual general meeting, passes resolutions by poll](https://longbridge.com/en/news/290534461.md)
- [PExA signs 10-system rental deal worth about SEK 7.5 million with top-10 pharma group](https://longbridge.com/en/news/290521966.md)
- [06:26 ETFDA monitoring failures cited in nearly a third of pharmaceutical warning letters and rising, according to Eupry](https://longbridge.com/en/news/290547956.md)
- [Heidelberg Pharma shareholders approve slate of AGM resolutions](https://longbridge.com/en/news/290573349.md)
- [PetroTal Announces Voting Results of Shareholders' Meeting | PTALF Stock News](https://longbridge.com/en/news/290650002.md)